APP in Pieces: βCTF implicated in Endosome Dysfunction
The Aβ peptide claims the lion’s share of attention from researchers, but lately, other metabolites are grabbing the spotlight as potential purveyors of pathology...
6381 RESULTS
Sort By:
The Aβ peptide claims the lion’s share of attention from researchers, but lately, other metabolites are grabbing the spotlight as potential purveyors of pathology...
We decided to try something novel and compile a roundup of the top news trends of the past year...
Mutations in the gene for α-synuclein, a small protein found in presynaptic terminals, were the first to be linked to familial Parkinson disease...
The mGluR5 modulator Norbin presents a possible new drug target for schizophrenia...
People with Alzheimer disease may be less likely to develop cancer, and people with cancer may have a lower risk of AD, according to a large population-based epidemiological study...
Just in time for the holidays, research shows that the protein that causes Huntington disease is liberally decked out with phosphates, acetyl groups, SUMO, and ubiquitin...
On 11 December 2009, the U.S. Food and Drug Administration (FDA) announced approval of a generic version of Aricept...
Our understanding of amyloid precursor protein’s (APP’s) effects on the cell gained new insight this week...
For all the scrutiny of the amyloid precursor protein (APP) as the source of pathogenic Aβ peptides, there is little understanding of the parent protein’s normal role in neurons...
The December 14 issue of Archives of Neurology features three papers and an editorial from scientists at Washington University in St Louis, Missouri...
Leptin, the satiety hormone that signals when to say when at big holiday feasts, also seems to guard against Alzheimer disease...
Partygoers familiar with conga line chaos probably know more about the formation of amyloid fibrils than they realize...
Researchers often divide their subjects by age in studies of memory, but it looks like they must also divide them by performance...
Tarenflurbil, aka flurizan, a γ-secretase modulator that showed promise in early preclinical and clinical trials, failed in Phase 3...
It appears that Dublin-based Elan's small molecule drug candidate ELND005 has run into some trouble...